Januvia

Product Description

Yanuvia belongs to the group of incretins. It is a highly selective inhibitor of DPP-4, the medicine has been widely used in the treatment of type 2 diabetes.

The drug is prescribed to patients with ineffectiveness of diet therapy in combination with optimal physical activity.

Januvia is indicated as one of the components of combined therapy with metformin, sulfonylureas or PPAR-γ activator when there is no proper effect on glycemic control while dieting and moderate motor activity.

In the triple scheme of therapy, Yanuvia is used in combination with sulfonylurea/metformin or metformin/agonist PPAR-γ, when the clinical effect of the double scheme is not enough.

Januvia can be used against the background of insulin therapy with insufficient effectiveness of such therapy.

Safety information

The daily amount of Yanuvia - 100 mg is taken once per os, regardless of food, in combination with other hypoglycemic agents or under conditions of monotherapy.

Contraindications

Yanuvia is not used in cases of excessive sensitivity to its constituents.

The medicine is prohibited for use in children and pregnant women, during lactation.

Insulin-dependent type of diabetes and ketoacidosis are direct contraindications to the use of Yanuvia.

Side effects

In the area of the respiratorytract in monotherapy Janow most common adverse reactions were infections of the upper parts of it, nasopharyngitis. A combined treatment with Yanuvia with insulin was often accompanied by a flu.

Allergic reactions were noted with almost the same frequency in patients who took Yanugia, with monotherapy or as part of a two-three-component scheme.

Hypoglycemic conditions were most prevalent among patients who took Yanuvia with sulfonylureas - up to 14%, taking it against insulin therapy led to hypoglycemic conditions with a frequency of 9%.

In the central nervous system, the most common adverse reactions were dizziness, cranialgia, and excessive drowsiness.

From the gastrointestinal tract, when Yanuvia was admitted, there was dyspeptic syndrome, flatulence, stool disorders, discomfort in the upper abdominal cavity.

With the combination of Yanuvia with PPAR agonists, peripheral edema was often noted in patients.